
Home » INOVIO APPLIES SKIN-BASED DRUG DELIVERY TECHNOLOGY TO DEVELOP ANTHRAX VACCINE
INOVIO APPLIES SKIN-BASED DRUG DELIVERY TECHNOLOGY TO DEVELOP ANTHRAX VACCINE
Inovio Biomedical is collaborating with RMR to license a technology for delivering gene-based therapeutics into skin -- a method called "electroporation" -- for a number of applications including an anthrax vaccine, the company said.
Inovio announced May 15 it had acquired rights to several patent families relating to the use of electroporation technology under a license with Sphergen SARL. The technology covers various skin electroporation methods, including a needle-less design using a flexible material that conforms to the skin contour.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
08Sep
-
15Sep
-
20Sep
-
21Sep
-
22Sep
-
11Oct